Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 6/20 | 0.98 |
| ▸ | RORC | P51449 | 5/20 | 0.98 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.98 |
| ▸ | USP2 | O75604 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.98 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.83 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.83 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.82 |
| ▸ | CRYAB | P02511 | 1/20 | 0.79 |
| ▸ | HMGCR | P04035 | 1/20 | 0.79 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.79 |
| ▸ | ITGAV | P06756 | 1/20 | 0.79 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.79 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.79 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.78 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.76 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.74 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL21707472 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL20607477 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21340667 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23761109 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21539517 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23365796 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21650234 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23579652 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21447271 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21445079 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260123975-A1 | DNA Fixing Machine | COLLADO FRANCISCO (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2023155352-A1 | TEST METHOD AND TEST KIT FOR LIPOPROTEIN CHOLESTEROL | 北京沃森赛瑟生物技术有限公司 | 2023-08-24 | — | — | WO | disclosed |
| CN-115969802-A | Medicinal use of sustained-release composition containing pirfenidone for treating and reversing human fatty hepatitis | 埃克斯卡利伯制药股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115461118-A | Compositions and methods for treating familial hypercholesterolemia and increased low density lipoprotein cholesterol | 萨利欧基因治疗公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-114214389-B | Lipoprotein cholesterol detection method and kit | 北京沃森赛瑟生物技术有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114214389-A | Lipoprotein cholesterol detection method and kit | 北京沃森赛瑟生物技术有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3125941-B1 | METHOD FOR DETERMINING THE OXIDIZING POWER OF HYDROPEROXIDES ROOH IN A BIOLOGICAL SAMPLE | H&D S R L (IT) | 2020-12-16 | — | — | EP | disclosed |
| US-10345318-B2 | Method for the diagnostic determination of the risk caused by an altered oxidative balance | H&D S.R.L. (IT) | 2019-07-09 | — | — | US | disclosed |
| US-20170184618-A1 | METHOD FOR THE DIAGNOSTIC DETERMINATION OF THE RISK CAUSED BY AN ALTERED OXIDATIVE BALANCE | CORNELLI, UMBERTO (IT) | 2017-06-29 | — | — | US | disclosed |
| EP-3125941-A1 | METHOD FOR THE DIAGNOSTIC DETERMINATION OF THE RISK CAUSED BY AN ALTERED OXIDATIVE BALANCE | H&D S.r.l. (IT) | 2017-02-08 | — | — | EP | disclosed |
| US-20040171548-A1 | Method of treatment of conditions by administration of streptolysin O | MILKHAUS LABORATORY, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004064766-A2 | METHOD OF TREATMENT OF CONDITIONS BY ADMINISTRATION OF STREPTOLYSIN O | MILKHAUS LABORATORY, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040146496-A1 | Method of treatment of connective tissue disorders by administration of streptolysin O | MILKHAUS LABORATORY, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003075924-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003070017-A2 | NOVEL SOY PROTEIN PRODUCTS | NUTRI PHARMA ASA (NO) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070018-A2 | FOOD PRODUCTS COMPRISING SOY PROTEIN | NUTRI PHARMA ASA (NO) | 2003-08-28 | — | — | WO | disclosed |
| US-20030073614-A1 | Methods for affecting various diseases utilizing LXR compounds | EXELIXIS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-20020052394-A1 | Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release | MASON R PRESTON (US) | 2002-05-02 | — | — | US | disclosed |
| WO-2002011723-A1 | SYNERGISTIC EFFECT OF AMLODIPINE AND ATORVASTATIN | MASON R PRESTON (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260123975-A1 | DNA Fixing Machine | GET3, MCM3, SMCHD1 | OSBP 4212/4885RORC 1298/4885OSBP2 4592/4885 |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | GCKR, HDAC5, GPR119 | OSBP 3044/4885RORC 1307/4885OSBP2 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.